NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ALDX Stock Alerts $3.94 +0.03 (+0.77%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.88▼$4.0050-Day Range$2.77▼$4.7252-Week Range$1.42▼$11.97Volume570,390 shsAverage Volume585,545 shsMarket Capitalization$232.07 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aldeyra Therapeutics alerts: Email Address Aldeyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.9% Upside$9.33 Price TargetShort InterestHealthy3.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.47 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector501st out of 907 stocksPharmaceutical Preparations Industry230th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.63% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 12.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 2.5 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aldeyra Therapeutics this week, compared to 3 articles on an average week.Search Interest22 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows12 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have bought 303.41% more of their company's stock than they have sold. Specifically, they have bought $1,473,245.00 in company stock and sold $365,194.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Aldeyra Therapeutics Stock (NASDAQ:ALDX)Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesApril 9, 2024 | insidertrades.comPerceptive Advisors Llc Purchases 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockApril 4, 2024 | insidertrades.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Acquires 8,374 SharesApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 18, 2024 | businesswire.comAldeyra Therapeutics to Host Research & Development Day on April 25, 2024April 15, 2024 | markets.businessinsider.comAttention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your BehalfApril 10, 2024 | investing.comPerceptive advisors buys Aldeyra Therapeutics shares worth $833kApril 4, 2024 | msn.comAldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingApril 3, 2024 | msn.comAldeyra gains as Oppenheimer upgrades on revised plans for lead assetApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 3, 2024 | finance.yahoo.comAldeyra's Dry Eye Disease Drug May Be on Path for FDA ApprovalApril 3, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The CornerApril 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)March 13, 2024 | finance.yahoo.comAldeyra Therapeutics Inc President and CEO Todd Brady Sells Company SharesMarch 11, 2024 | markets.businessinsider.comStrong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic PartnershipsFebruary 22, 2024 | finance.yahoo.comInstitutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the companyFebruary 14, 2024 | cnn.comIntellia Therapeutics, Inc.February 6, 2024 | finance.yahoo.comAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | benzinga.comAldeyra Therapeutics Stock (NASDAQ:ALDX), Guidance and ForecastJanuary 28, 2024 | seekingalpha.comWhy Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's ProspectsJanuary 4, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)January 4, 2024 | finance.yahoo.comAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesDecember 31, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)December 21, 2023 | markets.businessinsider.comOutperform Rating Affirmed on Aldeyra Therapeutics Following Positive ADX Developments and Expanding Treatment ProspectsDecember 21, 2023 | markets.businessinsider.comBuy Rating Affirmed for Aldeyra Therapeutics Amidst Clinical Advancements and Market PotentialDecember 19, 2023 | msn.comPositive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis StudyDecember 19, 2023 | marketwatch.comAldeyra Therapeutics Shares Rise 12% Following Positive Trial Results of ADX-629December 19, 2023 | seekingalpha.comAldeyra stock jumps 8% on dermatitis drug updatesSee More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+136.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.45% Return on Assets-24.24% Debt Debt-to-Equity RatioN/A Current Ratio6.64 Quick Ratio6.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book1.93Miscellaneous Outstanding Shares58,900,000Free Float54,597,000Market Cap$232.07 million OptionableOptionable Beta1.51 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsConduit PharmaceuticalsNASDAQ:CDTuniQureNASDAQ:QUREOvid TherapeuticsNASDAQ:OVIDAC ImmuneNASDAQ:ACIU2seventy bioNASDAQ:TSVTView All CompetitorsInsiders & InstitutionsDenali Advisors LLCBought 47,300 shares on 4/19/2024Ownership: 0.080%Kingswood Wealth Advisors LLCBought 15,000 shares on 4/15/2024Ownership: 0.025%Woodstock CorpBought 54,011 shares on 4/9/2024Ownership: 0.290%Perceptive Advisors LlcBought 37,712 shares on 4/5/2024Total: $178,754.88 ($4.74/share)Los Angeles Capital Management LLCBought 269,061 shares on 4/5/2024Ownership: 0.646%View All Insider TransactionsView All Institutional Transactions ALDX Stock Analysis - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price target for 2024? 3 brokers have issued 1-year price objectives for Aldeyra Therapeutics' shares. Their ALDX share price targets range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2024? Aldeyra Therapeutics' stock was trading at $3.51 on January 1st, 2024. Since then, ALDX stock has increased by 12.3% and is now trading at $3.94. View the best growth stocks for 2024 here. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,050,000 shares, an increase of 12.0% from the March 15th total of 1,830,000 shares. Based on an average daily volume of 585,700 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.6% of the company's shares are sold short. View Aldeyra Therapeutics' Short Interest. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13. What ETF holds Aldeyra Therapeutics' stock? Invesco Nasdaq Future Gen 200 ETF holds 11,339 shares of ALDX stock, representing 0.63% of its portfolio. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.65%), Woodstock Corp (0.29%), Denali Advisors LLC (0.08%) and Kingswood Wealth Advisors LLC (0.03%). Insiders that own company stock include Bruce Greenberg, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALDX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
